So far, this has been a tough quarter for some of the growth darlings of the medical technology sector. It's still somewhat early in the reporting cycle, but Intuitive Surgical (ISRG) and MAKO ...

NEW YORK (AP) -- Shares of molecular diagnostics company Cepheid rose Tuesday after the company said that demand for several of its GeneXpert tests were stronger than expected. THE SPARK: Cepheid said ...

What: Shares of Cepheid (NASDAQ: CPHD), a molecular diagnostics company, fell by more than 20% today on heavy volume after the company released its preliminary third quarter results. Digging into the ...

What:Shares ofCepheid, a developer of molecular diagnostic tests used in managing infectious diseases and cancer, plunged around 12% today after the company reported its second-quarter earnings ...

This week, we have volatility on our side. Milk it for all it's worth. Here's your play to make …. Market volatility brought on by the brief correction that we just saw (and could continue) ...

Cepheid (Nasdaq:CPHD) hit a new 52-week high Friday as it changed hands at $27.05 compared with its previous 52-week high of $27. Cepheid is currently trading at $27.05 with 15,126 shares changing ...

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30.

Cepheid [CPHD], a leading molecular diagnostics company and the developer of Xpert MTB/RIF, the rapid diagnostic test for Tuberculosis which was endorsed by the World Health Organization, will visit ...

Investors in Cepheid (NASD: CPHD) saw new options become available this week, for the March 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...